University of California San Francisco Medical Center Purchases BSD-2000 Hyperthermia System from BSD Medical

University of California San Francisco Medical Center Purchases BSD-2000 Hyperthermia System from BSD Medical

<0> BSD Medical CorporationDennis Gauger, 801-972-5555Fax: 801-972-5930 </0>

BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the prestigious University of California San Francisco Medical Center (UCSF Medical Center) has purchased a BSD-2000 Hyperthermia System (BSD-2000). UCSF Medical Center is one of the nation's top 10 hospitals, and is recognized throughout the world for innovative patient care and advanced technology (). UCSF Medical Center is one of the premier providers of cancer care in the world. The UCSF Medical Center Comprehensive Cancer Center received the prestigious designation of "comprehensive" from the National Cancer Institute and ranks sixth nationwide in National Cancer Institute research grants. UCSF Medical Center has 7,000 employees and numerous locations.

“We are excited to have the BSD-2000 placed in this prestigious cancer care facility," stated Harold Wolcott, BSD's President. “UCSF is one of the world's leading medical centers, and has a long history of providing innovative therapies, including hyperthermia. UCSF recently purchased a BSD-500 Hyperthermia System. We are pleased they have decided to also offer the innovative capabilities of the BSD-2000 to their patients."

The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at .

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.